Nilotinib-Induced Keratosis Pilaris

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Nilotinib is a second-generation Bcr-Abl tyrosine kinase inhibitor (TKI) used for imatinib-resistant chronic myeloid leukemia (CML).
• Cutaneous adverse drug reactions are a known concern with TKIs, including nilotinib.
• Identifying specific dermatological side effects is crucial for patient management.

Observation:

• A case of keratosis pilaris developed in a patient treated with nilotinib.
• The patient did not experience associated symptoms such as alopecia or pruritus.
• This presentation suggests a specific pattern of cutaneous reaction to nilotinib.

Findings:

• Nilotinib can induce keratosis pilaris as a distinct adverse drug reaction.
• The absence of other common cutaneous symptoms like hair loss or itching may characterize this specific side effect.
• This association requires further clinical recognition.

Implications:

• Increased awareness of nilotinib-induced keratosis pilaris is necessary for clinicians.
• Prompt identification and management of this reaction can improve patient adherence and oncologic outcomes.
• Further research into the mechanisms of TKI-induced dermatopathies is warranted.